Latest United States News

QEM has ranked the Vaught-Peck prospect as the leading target at its newly acquired Garden Valley project in Idaho after reviewing historical records of columbite, samarskite and other rare-metal minerals. The opportunity remains prospective rather than proven, with no modern drilling, assays or resource estimate yet reported.

Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.

Optiscan Imaging has reached an 84-case milestone in its live digital pathology study with Australian Clinical Labs, testing the InForm platform across a broad range of tissue types and disease settings. The data may support future regulatory submissions and commercial discussions, but the announcement does not disclose diagnostic accuracy metrics or regulatory approval.

VHM has taken Goschen from a permitted project to a more financeable development, with Iluka committing to buy all planned rare earth concentrate and providing A$40 million in convertible note funding. The company remains pre-revenue, has not made a Final Investment Decision and will need further funding before construction can begin.

OD6 Metals has extended its Rocket-Big Jim-Spar fluorspar corridor at Quinn in Nevada to approximately 700 metres, with six surface samples returning at least 97% CaF₂ and three reaching 99.9%. The results expand the project’s high-grade story, but remain based on selective rock-chip sampling rather than drilling.

Sovereign Metals says a simple add-on circuit at its Malawi project could generate US$722 million of pre-tax value from monazite by-product recovery. The opportunity is commercially striking, but remains a preliminary scoping result dependent on further testwork, approvals, funding and customer qualification.

Olympio Metals has begun field exploration across its Jacknife and Raven silver projects in the United States, with drilling at Jacknife expected to start imminently. A replacement announcement also strengthens the company’s description of a historical foreign estimate, while making clear that the estimate remains non-JORC and requires fresh verification.

Diablo Resources has exercised its option over 101 patented claims covering the historic Horn Silver Mine in Utah, bringing its broader 202-claim, 13.2 square kilometre project package together. The company will now rank targets, advance permitting and prepare for a maiden Horn Silver drilling program in 2026.

Elevra Lithium is positioning its Québec operations for a near-doubling in spodumene concentrate capacity, while guiding to modest production growth and sharply higher capital spending in FY27. The three-stage North American Lithium expansion is targeting 373,000 tonnes per year for an estimated US$271 million.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

OncoSil Medical has secured $5.6 million from its three largest institutional investors to fund commercial launches of its OncoSil device in the United States and Australia. The commitments follow FDA and TGA approvals and would lift pro-forma cash to $12.1 million once completed.

Elixinol Wellness has finalized the divestment of its US operations to Ananda Health, securing upfront and deferred payments totaling approximately A$465,000. This move refocuses the company on its Australian health and wellness portfolio while reducing exposure to US regulatory risks.